The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Sobenin, Igor A ^a,c   Pryanishnikov, Valentin V ^a   Kunnova, Lyudmila M ^b   Rabinovich, Yevgeny A ^b   Martirosyan, Danik M ^d   Orekhov, Alexander N ^a,c  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b Moscow Municipal Cardiology Health Center   (Russian Federation)

^c Institute for Atherosclerosis Research   (Russian Federation)

^d Functional Food Center Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLICOR; GARLIC EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; UNCLASSIFIED DRUG; ANTIOXIDANT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SUDDEN DEATH; TREATMENT DURATION; BLOOD; CHEMISTRY; GARLIC; MIDDLE AGED; SEX DIFFERENCE; TABLET; TREATMENT OUTCOME;

ALLIUM SATIVUM;

ADULT; AGED; ANTIOXIDANTS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; GARLIC; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; TABLETS; TREATMENT OUTCOME;

EID: 77957909277     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-119     Document Type: Article

References (34)

1. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. G Assmann P Cullen H Schulte, Circulation 2002 105 3 310 315 10.1161/hc0302.102575 11804985
2. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, JAMA 2002 288 2981 2997 10.1001/jama.288.23.2981 12479763
3. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Hata Yoshiya, American Journal of Clinical Nutrition 1996 64 767 71 8901799
4. Garlic: empiricism or science? G Aviello L Abenavoli F Borrelli R Capasso AA Izzo F Lembo B Romano F Capasso, Nat Prod Commun 2009 4 12 1785 96 20120123
5. Garlic reduces plasma lipids by inhibiting hepatic cholesterol and triacylglycerol synthesis. YY Yeh SM Yeh, Lipids 1994 29 189 93 10.1007/BF02536728 8170288
6. Water-soluble organosulfur compounds of garlic inhibit fatty acid and triglyceride synthesis in cultured rat hepatocytes. L Liu YY Yeh, Lipids 2001 36 395 400 10.1007/s11745-001-0734-4 11383692
7. Multiple inhibitory effects of garlic extracts on cholesterol biosynthesis in hepatocytes. R Gebhardt, Lipids 1993 28 613 9 10.1007/BF02536055 8394977
8. Cholesterol-lowering effects of garlic extracts and organosulfur compounds: human and animal studies. YY Yeh L Liu, J Nutr 2001 131 989S 93S 11238803
9. Garlic shows promise for improving some cardiovascular risk factors. RT Ackermann CD Mulrow G Ramirez CD Gardner L Morbidoni VA Lawrence, Arch Intern Med 2001 161 6 813 24 10.1001/archinte.161.6.813 11268223
10. Therapeutic actions of garlic constituents. KC Agarwal, Med Res Rev 2003 16 111 24 10.1002/(SICI)1098-1128(199601)16:1<111::AID-MED4>3.0.CO;2-5
11. Garlic and garlic derived compounds inhibit human squalene monooxygenase. N Gupta TD Porter, J Nutr 2001 131 1662 7 11385050
12. Garlic shows promise for improving some cardiovascular risk factors. RT Ackermann,, et al. Arch Intern Med 2001 161 813 24 10.1001/archinte.161.6.813 11268223
13. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Muenster (PROCAM) study. G Assmann P Cullen H Schulte, Circulation 2002 105 310 5 10.1161/hc0302.102575 11804985
14. Pocket guide to prevention of coronary heart disease. International Task Force for Prevention of Coronary Heart Disease, Grunwald, Germany: Borm Bruckmeier Verlag GmBH 2003
15. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. H Tunstall-Pedoe,, et al. Lancet 1999 353 1547 57 10.1016/S0140-6736(99)04021-0 10334252
16. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. A Bordia SK Verma KC Srivastava, Prostaglandins Leukot Essent Fatty Acids 1998 58 257 63 10.1016/S0952-3278(98)90034-5 9654398
17. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Muenster Study (PROCAM) using neural networks. R Voss,, et al. Int J Epidemiol 2002 31 1253 62 10.1093/ije/31.6.1253 12540731
18. The ILIB lipid handbook for clinical practice. AM Gotto Jr,, et al. Blood lipids and coronary heart disease New York: International Lipid Information Bureau 2000
19. Garlic as a lipid lowering agent - a meta-analysis. C Silagy A Neil, J R Coll Physicians Lond 1994 28 39 45 8169881
20. Garlic preparations for prevention of atherosclerosis. HK Berthold T Sudhop, Curr Opin Lipidol 1998 9 565 9 10.1097/00041433-199812000-00008 9868592
21. Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. A Bordia SK Verma KC Srivastava, Prostaglandins Leukot Essent Fatty Acids 1996 55 201 5 10.1016/S0952-3278(96)90099-X 8931120
22. Hypotensive effect of long-acting garlic tablets allicor (a double-blind placebo-controlled trial). IV Andrianova IV Fomchenkov AN Orekhov, Ter Arkh 2002 74 76 8 11980131
23. Hypertension and hyperlipidaemia: garlic helps in mild cases. W Auer,, et al. Br J Clin Pract Suppl 1990 69 3 6 2083170
24. Effect of garlic on blood lipids in patients with coronary heart disease. A Bordia, Am J Clin Nutr 1981 34 2100 3 7293938
25. Cardiovascular effects of garlic (Allium sativum): a review. E Ernst, Pharmatherapeutica 1987 5 83 9 3310019
26. A meta-analysis of the effect of garlic on blood pressure. CA Silagy HA Neil, J Hypertens 1994 12 463 8 10.1097/00004872-199404000-00017 8064171
27. Effect of the garlic tablets allicor on thrombocyte aggregation in vitro and ex vivo. IV Andrianova,, et al. Biull Eksp Biol Med 1997 124 97 100 10.1007/BF02445068 9303744
28. Use of allikor for the normalization of fibrinolysis and hemostasis in patients with chronic cerebrovascular diseases. IV Andrianova,, et al. Klin Med (Mosk) 2001 79 55 8 11811113
29. The chemistry of garlic and onions. E Block, Sci Am 1985 252 114 9 10.1038/scientificamerican0385-114 3975593
30. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. YY Yeh L Liu, J Nutr 2001 131 989S 93S 11238803
31. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. WB Kannel,, et al. Am Heart J 1986 112 825 36 10.1016/0002-8703(86)90481-3 3532744
32. Quantitative determination of allicin and alliin from garlic by HPLC. B Iberl,, et al. Planta Med 1990 56 320 6 10.1055/s-2006-960969 17221429
33. Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. J Stamler,, et al. Cardiology 1993 82 191 222 10.1159/000175868 8324780
34. Direct anti-atherosclerosis-related effects of garlic. AN Orekhov,, et al. Ann Med 1995 27 63 5 10.3109/07853899509031938 7742001